96950 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans Cytokines; Lymphokines; Interferons
Sub-classes:CAVIAR POLYPEPTIDES
#2COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER
#3COMPOSITIONS AND METHODS
#4HUMANIZED IMMUNODEFICIENT MOUSE MODELS
#5Enhanced adoptive cell therapy
#6In Vivo Genetic Engineering of Antigen Responsive Cells
#7Methods and Systems for Processing a Cell Culture
#8PHASE TRANSITION ADJUSTING ELEMENT AND USE THEREOF
#9EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#10VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME
#11COMPOSITIONS AND METHODS FOR TREATING METACHROMATIC LEUKODYSTROPHY DISEASE AND RELATED DISORDERS
#12Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#13ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)
#14PHARMACEUTICAL COMPOSITION FOR TREATING COLITIS OR COLORECTAL CANCER COMPRISING COLON-TARGETED S100A8/A9-DERIVED SPECIFIC PEPTIDE
#15COMPOSITIONS AND METHODS FOR MODULATING T CELL RESPONSES
#16MODIFIED T CELLS AND USES THEREOF
#17ANTIBODIES AGAINST S100A8 AND S100A9, HETERODIMER OF S100A8 AND S100A9, DETECTION KIT AND USE OF THE ANTIBODIES, HETERODIMER AND DETECTION KIT
#18COMPLEX COACERVATES OF LACTOFERRIN AND OSTEOPONTIN
#19HUMAN OSTEOPONTIN PROTEIN PRODUCTION IN PLANT SYSTEMS
#20RECOMBINANT AAV VECTORS FOR TREATING NEURODEGENERATIVE DISORDERS
#21GENE-MODIFIED PLURIPOTENT STEM CELL, IMMUNOCOMPETENT CELL DERIVED THEREFROM, METHOD FOR PRODUCING SAID CELLS, AND USE THEREOF
#22Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
#23IMMUNOGENIC FUSION PROTEINS AGAINST CORONAVIRUS
#24PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF
#25COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY
#26MICRO-ENGINEERED MODELS OF THE HUMAN EYE AND METHODS OF USE
#27MODIFIED IMMUNOGLOBULINS
#28ANTI-ROR1 CHIMERIC ANTIGEN RECEPTORS (CARS), CELLS EXPRESSING THE CARS AND RELATED METHODS
#29ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF
#30COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#31ENGINEERED IMMUNE EFFECTOR CELLS EXPRESSING EXOGENOUSLY INTRODUCED CYTOKINES
#32LOCALIZED DELIVERY OF ANTI-FUGETACTIC AGENT FOR TREATMENT OF CANCER
#33COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#34COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#35METHODS FOR INDUCING AN IMMUNE RESPONSE BY ADMINISTERING ACTIVATED MESENCHYMAL STEM CELLS
#36METHODS FOR GENERATING MECHANICALLY-RESPONSIVE CELLS AND USES THEREOF
#37COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY
#38PEPTIDE-MHC-IMMUNOGLOBULIN MULTIMERS AND METHODS OF USE THEREOF
#39MODULATION OF IFI16 AND STING ACTIVITY
#40COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS
#41NOVEL RECOMBINANT STRAIN OF MYCOBACTERIUM SMEGMATIS AND USE OF SAME
#42Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
#43MODIFICATION OF IMMUNE CELLS FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
#44DIAGNOSTIC METHODS FOR T CELL THERAPY
#45COMPOSITIONS COMPRISING CHEMERIN AND METHODS OF USE THEREOF
#46Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues
#47PEPTIDE CONJUGATES
#48IMPLANTABLE CONSTRUCTS FOR MODULATING AN IMMUNE RESPONSE
#49TESTOSTERONE-SPECIFIC AFFIBODY AND USES THEREOF
#50EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#51ENGINEERED IMMUNE CELL AND USE THEREOF
#52Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#53ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS
#54TARGETED CYTOKINES AND METHODS OF USE THEREOF
#55MIC-1 COMPOUNDS AND USES THEREOF
#56TRANSGENIC MOUSE MODELS SUPPORTING HUMAN INNATE IMMUNE FUNCTION
#57BI-FUNCTIONAL CHIMERIC PROTEINS AND USES THEREOF
#58METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALS
#59Method of treating cancer using disulfide-linked trimeric OX40L
#60EPHA3 AND MULTI-VALENT TARGETING OF TUMORS
#61A FUSION PROTEON OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) AND INTERLEUKIN-2 (IL-2) AND APPLICATIONS THEREOF
#62COMPOSITION FOR PREVENTING OR TREATING OSTEOARTHRITIS, COMPRISING MESENCHYMAL STEM CELL EXPRESSING TUMOR NECROSIS FACTOR-INDUCIBLE GENE 6
#63Twisted gastrulation polypeptides and uses thereof
#64COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#65Regulatory T cell epitopes
#66CYTOKINE COMBINATION
#67Nucleic Acid Compounds for Binding Growth Differentiation Factor 11
#68TREATMENT FOR NEURODEGENERATIVE DISEASES
#69Conjugates of Biomolecule and Use Thereof
#70FIBROBLAST-BASED IMMUNOTHERAPY OF GRAVES DISEASE
#71ANTIGEN-PRESENTING EXTRACELLULAR VESICLES, COMPOSITION CONTAINING SAME, AND METHOD FOR PRODUCTION THEREOF
#72Multifunctional Heteromultimeric Constructs
#73COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#74CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS
#75Compositions and methods for delivery of nucleic acids to cells
#76Compositions and methods for delivery of nucleic acids to cells
#77VEGF MINI-TRAPS AND METHOD OF USE THEREOF
#78FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES
#79Modified immunoglobulins
#80Compositions and methods for delivery of nucleic acids to cells
#81Compositions and Methods for Simultaneously Modulating Expression of Genes
#82MODIFIED ORTHOPOXVIRUS VECTORS
#83COMPOSITION FOR DETERMINATION OF CELL-MEDIATED IMMUNE RESPONSIVENESS
#84INHALED DELIVERY OF PEPTIDE MIMICS OF CXCL10 FOR TARGETED ANTI-FIBROTIC THERAPY
#85Ciliary Neurotrophic Factor Receptor Ligands and Methods of Using the Same
#86Coordinating gene expression using RNA destabilizing elements
#87Separation moieties and methods of use thereof
#88Ciliary Neurotrophic Factor Receptor Ligand-Binding Agents and Methods of Using the Same
#89COMPOSITIONS COMPRISING ALBUMIN-FMS-LIKE TYROSINE KINASE 3 LIGAND FUSION PROTEINS AND USES THEREOF
#90FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L)-BASED CHIMERIC PROTEINS
#91Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use
#92CARBAMOYL PHOSPHATE SYNTHATASE-1 FOR THE TREATMENT AND PREVENTION OF LIVER INJURY
#93NEW MYOKINES AND USES THEREOF
#94Zinc Finger Protein-Superoxide Dismutase Fusion Protein With Cell Membrane Penetrating Property
#95Derivatisation of Insulin with Polysaccharides
#96COMPOSITIONS INCLUDING DIFFERENT TYPES OF TRANSFER FACTOR
#97PERIOSTEAL SKELETAL STEM CELLS IN BONE REPAIR
#98ANGIOGENIC CONDITIONING TO ENHANCE CARDIAC CELLULAR REPROGRAMMING OF FIBROBLASTS OF THE INFARCTED MYOCARDIUM
#99COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES
#100MOLECULAR SIGNATURE OF CANCER
#101FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
#102Therapeutic and diagnostic agents for cancer
#103Methods and reagents for modulating macrophage phenotype
#104EXPOSED COLLAGEN-TARGETED FUSION CYTOKINE FOR IMMUNE MODULATION IN INVASIVE CANCERS AND LESIONS OF INFECTIONS
#105PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
#106BI-FUNCTIONAL ARGININE-GLYCINE-ASPARTIC ACID (RGD) PEPTIDES AND METHODS TO PROMOTE ANGIOGENESIS
#107Compositions and methods for treatment of bone associated diseases
#108Coordinating gene expression using RNA destabilizing elements
#109Modified T cells and uses thereof
#110Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
#111MODIFIED IMMUNOMODULATORY PEPTIDE
#112ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)
#113Purification and purity assessment of RNA molecules synthesized with modified nucleosides
#114Coordinating Gene Expression Using RNA Destabilizing Elements
#115Compositions and methods for targeted cytokine delivery
#116Modified activin A
#117Methods and Systems for Processing a Cell Culture
#118Artificially-manipulated neovascularization regulatory system
#119PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
#120Methods for inducing an immune response by administering activated mesenchymal stem cells
#121Biomaterials for 3D Cell Growth and Differentiation
#122MODIFIED NATURAL KILLER CELLS AND NATURAL KILLER CELL LINES HAVING INCREASED CYTOTOXICITY
#123Methods of administering mesenchymal stem cells activated by cytokines for enhancing immunosuppression
#124Ligand-binding molecule having adjustable ligand-binding activity
#125CYTOKINE FUSION POLYPEPTIDE AND CYTOKINE LIBRARY COMPRISING SAME
#126Method of producing Th9 T-cells
#127IPSC-DERIVED SECRETOME COMPOSITIONS, AND RELATED SYSTEMS AND METHODS
#128In Vivo Genetic Engineering of Antigen Responsive Cells
#129Methods of inhibiting integrin α9β1 activity
#130The IgM and IgE Heavy Chain Domain 2 as Covalently Linked Homodimerization Modules for the Generation of Fusion Proteins with Dual Specificity
#131Composition and methods for disruption of bacterial biofilms without accompanying inflammation
#132Nucleic acid compounds for binding growth differentiation factor 11
#133CHIMERIC ANTIGEN RECEPTOR
#134Micro-engineered models of the human eye and methods of use
#135Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
#136TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE
#137Methods to Determine the Presence of an Antibody that Binds Modified Human Thymic Stromal Lymphopoietin (TSLP)
#138FLT3L-FC fusion proteins
#139PLASMID CONSTRUCTS FOR HETEROLOGOUS PROTEIN EXPRESSION AND METHODS OF USE
#140ALLOGENEIC T-CELL-BASED HIV VACCINE TO INDUCE CELLULAR AND HUMORAL IMMUNITY
#141Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
#142Exosomes for immuno-oncology and anti-inflammatory therapy
#143Enhanced adoptive cell therapy
#144MODIFIED IMMUNOMODULATORY PEPTIDE
#145Peptide conjugates
#146HISTAMINE-RELEASING FACTOR (HRF), HRF-RECEPTOR AND METHODS OF MODULATING INFLAMMATION
#147ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE
#148HUMANIZED TRANSGENIC ANIMAL
#149EPHA3 and multi-valent targeting of tumors
#150SINGLE-CHAIN LIGHT RECEPTOR AGONIST PROTEINS
#151Regulatory T cell epitopes
#152Combined preparations of PKM2 modulators and HMGB1
#153Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
#154Binding inhibitor between TCTP dimer type IgE-dependent histamine releasing factor and receptor thereof, and use thereof
#155Antigenic Proteins and Methods Therefor
#156Cytokine combination
#157Method treating malignant ascites and metastatic pleural effusion with and disulfide-linked trimeric TRAIL
#158Method for treating cancer using disulfide-linked trimeric 4-1BBL
#159Compositions and methods for adoptive cell therapy for cancer
#160Method for producing monomeric and multimeric molecules and uses thereof
#161Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
#162Recombinant adenovirus-based interferon biotherapeutics in swine
#163Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins
#164Activatable antibodies and methods of use thereof
#165Compositions including different types of transfer factor
#166Mast cell stabilizers for treatment of fever
#167Mast cell stabilizers for treatment of hypercytokinemia and viral infection
#168Compositions and methods for expansion of embryonic hematopoietic stem cells
#169AIMP1 protein fragment and skin-protecting composition containing same as active ingredient
#170METHODS FOR MODULATING PRODUCTION PROFILES OF RECOMBINANT PROTEINS
#171Multifunctional heteromultimeric constructs
#172Coordinating gene expression using RNA destabilizing elements
#173Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
#174Ciliary neurotrophic factor receptor ligand-binding agents and methods of using the same
#175Recombinant proteins and uses thereof
#176ANGIOGENIC CONDITIONING TO ENHANCE CARDIAC CELLULAR REPROGRAMMING OF FIBROBLASTS OF THE INFARCTED MYOCARDIUM
#177HMGB1 tyrosine mutants
#178Coordinating gene expression using RNA destabilizing elements
#179IL-31 ANTIBODY COMPOSITIONS
#180Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
#181Ciliary neurotrophic factor receptor ligands and methods of using the same
#182NOVEL IMMUNOCONJUGATES
#183Immunoconjugates
#184Methods of treating a disorder associated with with insufficient stimulator of interferon genes (STING) activity
#185Methods and reagents for modulating macrophage phenotype
#186Conditionally Active Biological Proteins
#187MACROPHAGES REDIRECT PHAGOCYTOSIS BY NON-PROFESSIONAL PHAGOCYTES AND INFLUENCE INFLAMMATION
#188Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligands
#189Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
#190CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS
#191CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF
#192Musclin peptides and methods of use thereof
#193Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
#194Compositions and methods for treatment of bone associated diseases
#195Coordinating gene expression using RNA destabilizing elements
#196Derivatisation of Insulin with Polysaccharides
#197METHOD TO IMPROVE THE EFFECTIVENESS OF ANTI-CANCER THERAPIES BY EXPOSING CANCER CELLS TO AN INFLAMMATORY STIMULUS PRIOR TO TREATMENT
#198Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
#199Method of altering an antibody-related adverse event based on SCD163 and/or CXCL5 levels
#200Exosomes for immuno-oncology and anti-inflammatory therapy
#201Immunomodulatory polypeptides and related compositions and methods
#202Compositions and methods for modulating γ-c-cytokine activity
#203Stimulation of Regenerative Processes and Factors by Noble Gases
#204Vascular endothelial growth factor antagonists
#205Plasmid constructs for heterologous protein expression and methods of use
#206Bi-functional chimeric proteins and uses thereof
#207Vaccines with biomolecular adjuvants
#208SUPPRESSION OF CANCER
#209COMPOSITIONS AND METHODS FOR TISSUE REPAIR
#210Compositions and methods for targeted cytokine delivery
#211Peptide for preventing or treating inflammatory diseases and use thereof
#212ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)
#213CHIMERIC ANTIGEN RECEPTOR
#214Mast cell stabilizers for treatment of hypercytokinemia and viral infection
#215L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
#216Skin probiotic formulation
#217Methods of producing activated mesenchymal stem cells
#218METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLS
#219Nucleic acid compounds for binding growth differentiation factor 11
#220Monoclonal antibody FnAb8 and application thereof
#221Fusokines involving cytokines with strongly reduced receptor binding affinities
#222Compositions comprising chemerin and methods of use thereof
#223Immune function development promoter and growth promoter
#224VEGF VARIANT POLYPEPTIDE COMPOSITIONS
#225Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
#226ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR MONOCLONAL ANTIBODIES
#227Diagnostic methods for T cell therapy
#228MIC-1 compounds and uses thereof
#229Auto-injector with signaling cap
#230Expression of Mammalian Proteins in Pseudomonas Fluorescens
#231N-Terminal Polysialylation
#232Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof
#233Localized delivery of anti-fugetactic agent for treatment of cancer
#234Single-chain light receptor agonist proteins
#235EPHA3 and multi-valent targeting of tumors
#236Molecular signature of cancer
#237Peptide conjugates
#238Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
#239Polypeptide having chemokine activity and uses thereof
#240Method of preparing physiologically active polypeptide conjugate
#241Compositions and methods for expansion of embryonic hematopoietic stem cells
#242Modified natural killer cells and natural killer cell lines having increased cytotoxicity
#243ANTI-ANGIOGENIC VEGF-AX ISOFORM
#244MUSCLIN PEPTIDES AND METHODS OF USE THEREOF
#245Libraries of modified fibronectin type III tenth domain-containing polypeptides
#246IL-31 ANTIBODY COMPOSITIONS
#247MULTIMERIC CONSTRUCTS
#248Fusokines involving cytokines with strongly reduced receptor binding affinities
#249Oligopeptide having proinflammatory cytokine secretion-inhibiting activity
#250RECOMBINANT ONCOLYTIC VIRUSES AND USES THEREOF
#251Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
#252Bi-functional arginine-glycine-aspartic acid (RGD) peptides and methods to promote angiogenesis
#253METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR
#254Lactococcus lactis producing TSLP or IL-25 and their uses as probiotics and therapeutics
#255Fusion Proteins for Modulating Regulatory and Effector T Cells
#256MACROPHAGE ACTIVATING FACTOR FOR TREATING BENIGN OR PRECANCEROUS PAPILLOMAS
#257Mast cell stabilizers for treatment of hypercytokinemia and viral infection
#258Mast cell stabilizers for treatment of hypercytokinemia and viral infection
#259STRUCTURE AND FUNCTION OF THE SALICYCLIC ACID BINDING SITES ON HUMAN HMGB1 AND METHODS OF USE THEREOF FOR THE RATIONAL DESIGN OF BOTH SALICYCLIC ACID DERIVATIVES AND OTHER AGENTS THAT ALTER ANIMAL AND PLANT HMGBS ACTIVITIES
#260Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein
#261Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
#262Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides
#263Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
#264Use of MIF and MIF pathway agonists
#265Treatment of right ventricular dysfunction due to pressure overload
#266Cytokine fusion proteins
#267Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11
#268Chloroplast Expressing Colostrum or Milk Polypeptides
#269Method for producing monomeric and multimeric molecules and uses thereof
#270CHIMERIC PROTEIN
#271FcRn-TARGETED ANTIGEN FUSION PROTEINS
#272Purification and purity assessment of RNA molecules synthesized with modified nucleosides
#273IgM and IgE heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
#274Methods of treating liver conditions using Notch2 antagonists
#275Chemokine-cytokine fusion proteins of SDF-1 and CD40L
#276Cytokine-based fusion proteins for treatment of immune disorders
#277Methods of producing a zcytor17 heterodimeric cytokine receptor
#278Activation of adaptive immune processes for the treatment of cancers and infectious diseases
#279Vascular endothelial growth factor antagonists and methods of making
#280Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
#281Co-expression plasmid
#282REGULATION OF ENDOGENOUS GENE EXPRESSION IN CELLS USING ZINC FINGER PROTEINS
#283Tumor infiltrating cells engineered to express a pro-inflammatory polypeptide
#284LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors
#285Method of designing a peptide and/or peptide derivative for modulating gamma-c-cytokine activity
#286Conditionally active biological proteins
#287Binding inhibitor between TCTP dimer type IGE-dependent histamine releasing factor and receptor thereof, and use thereof
#288Enhanced adoptive cell therapy
#289Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
#290Immunoconjugates
#291Apelin analogues
#292N-terminal derivatisation of proteins with polysaccharides
#293Dual targeting drug carrier and application thereof
#294Expression of mammalian proteins in
#295Process for the purification of a growth factor protein
#296Methods of developing selective peptide antagonists
#297Engineered cytokine- and chemokine-expressing strains and methods of use
#298Colostrum/milk protein compositions
#299Fusion proteins for modulating regulatory and effector T cells
#300Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins